ArticlePediatric cardiology2026
Lipid Screening and Dyslipidemia in Children with Congenital Heart Disease.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyslipidemia is associated with increased risk for atherosclerosis and cardiovascular events in adulthood. Atherosclerosis begins in childhood and guidelines exist to screen for at-risk children. Children with congenital heart disease (CHD) have high lifetime cardiovascular risk but data are limited on their rates of dyslipidemia. Our study aims to detail rates of lipid screening and dyslipidemia in children with CHD. Children with CHD aged 9-18 years who followed at our institution from 2012 to 2019 were included. Subjects were classified as dyslipidemic if they met one of the following: total cholesterol ≥ 200 mg/dL, low-density lipoprotein-C ≥ 130 mg/dL, triglycerides ≥ 130 mg/dL, high-density lipoprotein cholesterol [HDL-C] < 40 mg/dL, non-HDL-C ≥ 145 mg/dL. Of 1579 patients, only 11.3% (N = 179/1579) had a documented lipid panel. Of those screened, 60% (N = 107/179) had dyslipidemia. Screened subjects had higher median BMI percentiles versus unscreened (84th vs. 64th ). Dyslipidemic subjects had higher median BMI percentiles compared to those without (92nd vs. 74th ). Black patients were a higher proportion of the screened population compared to unscreened (26% vs. 11%). Overall, there were similar rates of dyslipidemia across all races and CHD lesions. Only a small proportion of children with CHD had lipid screening performed despite universal screening guidelines. However, a sizable percentage of children screened had dyslipidemia. Screening favored Black patients and those with higher BMI. Higher BMI patients had increased rates of dyslipidemia. These findings emphasize the importance of universal screening for dyslipidemia in children with CHD.
Indexed as
Identifiers
42400604What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.